Prognostic biomarkers in ST-segment elevation myocardial infarction: a step toward personalized medicine or a tool in search of an application?

n recent years, much effort has been devoted to risk tratification of patients with acute coronary syndromes ACS), mainly focusing on patients with non–ST-segment levation (NSTE)-ACS. In this category of patients, bioarkers have been proven to be useful for: 1) the troubleome diagnosis; 2) therapeutic and strategic decision makng (guiding the choice of more potent therapies, the ndication and timing of invasive treatment, or both); 3) the ong-term prognostication; and 4) a better understanding of he complex pathophysiological mechanisms (1–6). Scoring ystems have been created that also include up to 3 biomarers in addition to clinical variables (7). The studies pubished in these fields have made the history and the fortune f biomarkers in cardiology, leading, for example, to the xtensive use of troponins and the recognition of inflamation as a fundamental player in plaque rupture.